168 related articles for article (PubMed ID: 11960356)
1. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link.
Kuttler F; Valnet-Rabier MB; Angonin R; Ferrand C; Deconinck E; Mougin C; Cahn JY; Fest T
Leukemia; 2002 Apr; 16(4):726-35. PubMed ID: 11960356
[TBL] [Abstract][Full Text] [Related]
2. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2.
Mainou-Fowler T; Overman LM; Dignum H; Wood K; Crosier S; Angus B; Proctor SJ; Anderson JJ
Int J Oncol; 2008 Jan; 32(1):59-68. PubMed ID: 18097543
[TBL] [Abstract][Full Text] [Related]
3. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
Bavi P; Abubaker J; Hussain A; Sultana M; Al-Dayel F; Uddin S; Al-Kuraya KS
Hum Pathol; 2008 Jun; 39(6):885-94. PubMed ID: 18400256
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
[TBL] [Abstract][Full Text] [Related]
5. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma.
Azuhata T; Scott D; Takamizawa S; Wen J; Davidoff A; Fukuzawa M; Sandler A
J Pediatr Surg; 2001 Dec; 36(12):1785-91. PubMed ID: 11733907
[TBL] [Abstract][Full Text] [Related]
6. Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes.
Bai M; Skyrlas A; Agnantis NJ; Kamina S; Kitsoulis P; Kanavaros P
Anticancer Res; 2004; 24(5A):3081-8. PubMed ID: 15517919
[TBL] [Abstract][Full Text] [Related]
7. STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation.
Lassmann S; Schuster I; Walch A; Göbel H; Jütting U; Makowiec F; Hopt U; Werner M
J Clin Pathol; 2007 Feb; 60(2):173-9. PubMed ID: 17264243
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer.
Ai Z; Yin L; Zhou X; Zhu Y; Zhu D; Yu Y; Feng Y
Cancer; 2006 Aug; 107(4):746-56. PubMed ID: 16826583
[TBL] [Abstract][Full Text] [Related]
9. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Tracey L; Pérez-Rosado A; Artiga MJ; Camacho FI; Rodríguez A; Martínez N; Ruiz-Ballesteros E; Mollejo M; Martinez B; Cuadros M; Garcia JF; Lawler M; Piris MA
J Pathol; 2005 Jun; 206(2):123-34. PubMed ID: 15880597
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma.
Filipits M; Jaeger U; Pohl G; Stranzl T; Simonitsch I; Kaider A; Skrabs C; Pirker R
Clin Cancer Res; 2002 Mar; 8(3):729-33. PubMed ID: 11895902
[TBL] [Abstract][Full Text] [Related]
11. Centroblastic diffuse large B cell lymphoma displays distinct expression pattern and prognostic role of apoptosis resistance related proteins.
Faccion RS; Rezende LM; Romano Sde O; Bigni Rde S; Mendes GL; Maia RC
Cancer Invest; 2012 Jun; 30(5):404-14. PubMed ID: 22571341
[TBL] [Abstract][Full Text] [Related]
12. Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes.
Watanuki-Miyauchi R; Kojima Y; Tsurumi H; Hara T; Goto N; Kasahara S; Saio M; Moriwaki H; Takami T
Pathol Int; 2005 Jun; 55(6):324-30. PubMed ID: 15943789
[TBL] [Abstract][Full Text] [Related]
13. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
[TBL] [Abstract][Full Text] [Related]
14. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
Obermann EC; Csato M; Dirnhofer S; Tzankov A
J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
[TBL] [Abstract][Full Text] [Related]
15. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL).
Markovic O; Marisavljevic D; Cemerikic V; Perunicic M; Savic S; Filipovic B; Mihaljevic B
Eur J Haematol; 2011 Mar; 86(3):246-55. PubMed ID: 21198858
[TBL] [Abstract][Full Text] [Related]
16. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients.
Amen F; Horncastle D; Elderfield K; Banham AH; Bower M; Macdonald D; Kanfer E; Naresh KN
Histopathology; 2007 Jul; 51(1):70-9. PubMed ID: 17593082
[TBL] [Abstract][Full Text] [Related]
17. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
18. Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma.
Dierlamm J; Murga Penas EM; Bentink S; Wessendorf S; Berger H; Hummel M; Klapper W; Lenze D; Rosenwald A; Haralambieva E; Ott G; Cogliatti SB; Möller P; Schwaenen C; Stein H; Löffler M; Spang R; Trümper L; Siebert R;
Haematologica; 2008 May; 93(5):688-96. PubMed ID: 18367485
[TBL] [Abstract][Full Text] [Related]
19. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma.
Bedewy AM; Elgammal MM; Bedewy MM; El-Maghraby SM
Ann Hematol; 2013 Oct; 92(10):1359-67. PubMed ID: 23652586
[TBL] [Abstract][Full Text] [Related]
20. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
